|
CIBMTR is a research collaboration between the NMDP/Be The Match and Medical College of Wisconsin.
|
|
CIBMTR Center Information Maintenance
CIBMTR Center Maintenance must keep your center's data management staff information up-to-date. If center changes are submitted using the User Access Form that is on the NMDP website, CIBMTR does not receive the information. The form goes to the NMDP Service Desk and not to CIBMTR.
We request that your center's CIBMTR Primary Data Contact additionally send change information directly to: cibmtr-centermaintenance@nmdp.org. Include your CIBMTR Center Number (CCN) in the email.
Here are examples of changes to send :
- New staff members
- Full name, email, and job role
- Changes in job roles at the center
- Is someone taking over as primary contact?
- Is there a new medical director?
- Departing staff
- If applicable, include information about who is taking over their role
- Basic contact information changes
- Name, title, job role, e-mail, etc.
- Center changes
- New center address, change in transplant types performed, etc.
The Center Personnel Change Form has been removed from the CIBMTR website.
|
New eLearning
Now available in the Learning Center is a new module titled: "Reporting Preparative Regimen on the Pre-TED (Form 2400) and Baseline (Form 2000)" authored by CIBMTR auditors Matt Petcoff, Katie Newcomb and Kathleen Kane. The module includes specific instruction on how to correctly report drug dosing, regimen intensity and unique reporting issues related to the preparative regimen. We encourage all data managers to review the module and test your knowledge in this important reporting area.
Approximately 25 minutes in length.
|
Access to the Learning Center
Remember, as of February 2015, the Learning Center program was modified and has improved functionality.
1) NEW Users to this Learning Center will need to set up an account.
When setting up a new account, please:
− Indicate your Primary Center Type as CIBMTR/Research Center
− Indicate your Secondary Center Type as Transplant Center
− In the Group Selection section, select the checkbox next to Network.
It may take up to two business days for your new user account registration to become active, before it allows you to access the training. If you still do not have access after two days, please contact Lori Colt, Training Specialist - lcolt@nmdp.org
2) To Access an eLearning:
- In the Course Catalog window set filter for CIBMTR Data Management
- Search for the eLearning title.
- Click on the link 'Add to My Learning' . It will populate in the 'My Learning' pane.
- Click on the course title link in the 'Activity Tree' to launch the module.
- At the end of the eLearning, click on the Exit tab, to return to the 'Activity Tree'
- Complete all activities there - (Exam, Evaluation, etc.)
- Print certificate(s) of completion, optional
- Save a copy of your certificate, optional
|
Question: Reporting monoclonal and polyclonal plasma cells in MM
Laboratory and pathology reports often contain the words 'monoclonal' or 'polyclonal' when describing plasma cells. Could you explain which of these should be reported regarding multiple myeloma on Forms 2016 and 2116?
Answer:
Report all the plasma cells whether or not they are identified as monoclonal or polyclonal. The definition of "clonal" is - cells that arise from a single cell lineage. The definition of "monoclonal" is: forming a clone that is derived from a single cell. Basically, "clonal" and "monoclonal" mean the same thing. The definition of polyclonal is - consisting of, or derived from many clones. Polyclonal cells are non-pathologic (i.e., not cancerous). If a bone marrow pathology report identifies monoclonal and polyclonal plasma cells, add the percentages together to report on Forms 2016 and 2116.
Question: Assessing heart valve disease comorbidity
Scenario: The patient's History & Physical record shows left ventricular hypertrophy, mild mitral regurgitation, moderate to moderately sever tricuspid regurgitation, mild pulmonary hypertension, and trace pulmonary regurgitation. Should this be reported as a heart valve disease comorbidity?
Answer:
In the case above, the patient's moderate to moderately severe tricuspid regurgitation, would qualify for reporting "yes" to the heart valve disease comorbidity. If there's at least moderate to severe degree of valve stenosis or insufficiency, then heart valve disease comorbidity should be reported as "yes".
The term 'insufficiency' is synonymous with 'regurgitation'. Centers should not report mitral valve insufficiency/regurgitation, mitral valve prolapse or valve regurgitation in the "other specify field".
|
